Pityriasis Rubra Pilaris, Refractory to IL-17A Inhibition, with Rapid Improvement Following IL-17A/IL-17F Blockade by Bimekizumab. (2024). SKIN The Journal of Cutaneous Medicine, 8(6), 1987-1992. https://doi.org/10.25251/skin.8.6.13